| Drug Name |
Anakinra |
| Drug ID |
BADD_D00141 |
| Description |
Anakinra is a recombinant, nonglycosylated human interleukin-1 receptor antagonist (IL-1Ra). The difference between anakinra and the native human IL-1Ra is that anakinra has an extra methionine residue at the amino terminus. It is manufactured by using the E. coli expression system. Anakinra is composed of 153 amino acid residues. FDA approved on November 14, 2001 for the treatment of rheumatoid arthritis. |
| Indications and Usage |
For the treatment of adult rheumatoid arthritis and treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID). |
| Marketing Status |
approved |
| ATC Code |
L04AC03 |
| DrugBank ID |
DB00026
|
| KEGG ID |
D02934
|
| MeSH ID |
D053590
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D02DES
|
| NDC Product Code |
68225-067; 66658-234 |
| UNII |
9013DUQ28K
|
| Synonyms |
Interleukin 1 Receptor Antagonist Protein | IL1 Febrile Inhibitor | Febrile Inhibitor, IL1 | IL-1Ra | Urine-Derived IL1 Inhibitor | IL1 Inhibitor, Urine-Derived | Urine Derived IL1 Inhibitor | IL-1 Inhibitor, Urine | IL 1 Inhibitor, Urine | Urine IL-1 Inhibitor | Interleukin 1 Inhibitor, Urine | Antril | Kineret | Anakinra |
